RxDoctor Payments Data

Chetan Lokhande, MD

Interventional Cardiology · Fayetteville, NCNPI 1649658808

Payments from drug & device makers

$6,121in general payments, 2019–2025

Across 98 payments — averaging $62.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Medtronic$237
  • Merck$188
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • Actelion Pharmaceuticals US, Inc.$151
  • plus $768 from 17 others

What the payments were for

  • Travel & lodging$2,89247%
  • Food & beverage$2,72845%
  • Education$5018%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,121 in reported general payments places this provider in the 40th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$165,345
Medicare patients
774
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$87,593
EntrestoSacubitril/Valsartan61$66,639
JardianceEmpagliflozin25$25,521
FarxigaDapagliflozin Propanediol27$20,043
BrilintaTicagrelor19$10,364
Metoprolol Succinate125$1,172
Lisinopril58$770
Carvedilol56$646
Atorvastatin Calcium116$578
Losartan Potassium62$527
Rosuvastatin Calcium56$512
Amlodipine Besylate140$478
Spironolactone52$416
Amiodarone Hcl14$364
Isosorbide Mononitrate ErIsosorbide Mononitrate65$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$87,59393 claims
NovartisEntresto$81$66,63961 claims
AstraZenecaFarxiga, Brilinta$59$30,40746 claims
Boehringer IngelheimJardiance$131$25,52125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →